Michael C. Creedon Jr. has been appointed interim CEO upon Rick Dreiling's stepping down as chairman and CEO, effective Nov. 3 due to health challenges.
Orlynvah is used to treat uncomplicated urinary tract infections caused by certain microorganisms in adult women who have limited or no alternative oral antibacterial treatment options.
Francois Mandeville was named executive vice president, strategy and M&A; Pawan Verma was named executive vice president, chief data and information officer.